Analyst Ratings For GALAPAGOS NV/S ADR (NASDAQ:GLPG)
Today, HC Wainwright reiterated its Buy rating on GALAPAGOS NV/S ADR (NASDAQ:GLPG) with a price target of $150.00.
There are 10 Buy Ratings, 2 Hold Ratings, 1 Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on GALAPAGOS NV/S ADR (NASDAQ:GLPG) is Buy with a consensus target price of $129.10 per share, a potential 4.04% upside.
Some recent analyst ratings include
- 6/12/2019-GALAPAGOS NV/S ADR (NASDAQ:GLPG) had its Buy rating reiterated by HC Wainwright with a $150.00 price target
- 5/2/2019-GALAPAGOS NV/S ADR (NASDAQ:GLPG) had its Buy rating reiterated by Cantor Fitzgerald with a $130.00 price target
- 2/22/2019-GALAPAGOS NV/S ADR (NASDAQ:GLPG) had its Buy rating reiterated by Cowen
- 2/22/2019-GALAPAGOS NV/S ADR (NASDAQ:GLPG) has coverage initiated with a Outperform rating and $140.00 price target
- 2/22/2019-GALAPAGOS NV/S ADR (NASDAQ:GLPG) has coverage initiated with a Outperform rating
- 12/13/2018-GALAPAGOS NV/S ADR (NASDAQ:GLPG) gets upgraded to Outperform by Credit Suisse Group
About GALAPAGOS NV/S ADR (NASDAQ:GLPG)
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. Read More…
Recent Trading Activity for GALAPAGOS NV/S ADR (NASDAQ:GLPG)
Shares of GALAPAGOS NV/S ADR closed the previous trading session at 124.46 up +1.71 1.39% with 124.46 shares trading hands.
